Quick Answer
Immuneering Corp reported Net Income Loss of -$56.02 million for the year ending 2025.
- Immuneering Corp showed an increase of +8.2% in Net Income Loss from 2024 to 2025.
- This data is from Immuneering Corp's annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$3.20 million | Q2 2020: -$3.60 million | Q3 2020: -$4.40 million | Q1 2021: -$6.23 million | Q2 2021: -$7.99 million | Q3 2021: -$8.53 million | Q1 2022: -$12.90 million | Q2 2022: -$11.53 million | Q3 2022: -$12.84 million | Q1 2023: -$13.60 million | Q2 2023: -$12.19 million | Q3 2023: -$12.60 million | Q1 2024: -$14.31 million | Q2 2024: -$14.08 million | Q3 2024: -$14.60 million | Q1 2025: -$15.05 million | Q2 2025: -$14.43 million | Q3 2025: -$14.96 million.
- Over the full 6 years of available data (2020 to 2025), Immuneering Corp's Net Income Loss has declined by 228.8%.
- Historical annual values: Fiscal year 2025: -$56.02 million | Fiscal year 2024: -$61.04 million | Fiscal year 2023: -$53.47 million | Fiscal year 2022: -$50.51 million | Fiscal year 2021: -$33.54 million | Fiscal year 2020: -$17.04 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: